Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Deborah Goberdhan and her team have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.

Image: 'Tumours - Cancer cells seek nutrients from the body in order to grow’

Cancer cellA team from Oxford University’s Department of Physiology, Anatomy and Genetics led by Dr Deborah Goberdhan worked with cancer doctor and researcher, Professor Adrian Harris, to understand the effects of this protein called PAT4.

Dr Goberdhan said: ‘We found that aggressive cancer cells manufacture more PAT4, which enables them to make better use of available nutrients than the cells around them – including healthy tissue.’

Cancer cells often have restricted access to the body’s nutrient-rich blood supply. The ability to sense and acquire nutrients is critical for a cancer to grow.

Dr Goberdhan’s and Prof Harris’s groups collaborated to develop an antibody that could be used to highlight PAT4 in human tissue samples. This was then used to study anonymous tumour samples taken from patients with colorectal cancer, a common form of the disease.

The results were compared to the known outcomes for the patients. Those who had higher levels of PAT4 in their tumours did less well than those with lower levels – being more likely to relapse and die.

The researchers then looked at what happened when PAT4 levels were reduced. They showed that by reducing PAT4 levels, cancerous tumours grew more slowly.

Dr Goberdhan said: ‘These findings support each other. Not only do higher levels of PAT4 mean a worse outcome, but lowering levels improves the situation. This means that we have identified a mechanism which cancer cells prefer to use and which we might be able to target as part of a combination treatment.’

The research, funded by Cancer Research UK, the Wellcome Trust and the Biotechnology and Biological Sciences Research Council is published in the science journal Oncogene on 5 October 2015. It continues and may eventually provide a way of increasing survival from cancer.

The paper, PAT4 levels control amino acid sensitivity of rapamycin-resistant mTORC1 from the golgi and affect clinical outcome in colorectal cancer, appears in the journal Oncogenedoi:10.1038/onc.2015.363.

Source: University of Oxford website

 

See also:

  • Article in the Mirror
  • Articles in the Daily Telegraph and the Sun (images below)

The Daily Telegraph

 The Sun

Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.

Collaborative MRC grant paves the way to new therapeutic targets for stress and anxiety disorders

Dr Armin Lak, Associate Professor Ed Mann and Professor Zoltán Molnár have been awarded a £733K Project Grant from the Medical Research Council on “Orexinergic projections to neocortex: potential role in arousal, stress and anxiety-related disorders”.